Patents by Inventor Holger Lode

Holger Lode has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230340148
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Application
    Filed: September 19, 2022
    Publication date: October 26, 2023
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
  • Patent number: 11447565
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 20, 2022
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Publication number: 20180134801
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Application
    Filed: September 11, 2017
    Publication date: May 17, 2018
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
  • Patent number: 9777068
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: October 3, 2017
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Publication number: 20150139942
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Application
    Filed: July 31, 2012
    Publication date: May 21, 2015
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Publication number: 20070036751
    Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
    Type: Application
    Filed: September 26, 2006
    Publication date: February 15, 2007
    Inventors: Holger Lode, Ralph Reisfeld, David Cheresh, Stephen Gillies
  • Publication number: 20060293254
    Abstract: The invention relates to podophyllotoxins, uses thereof and methods of their production.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 28, 2006
    Inventors: Gerhard Gaedicke, Holger Lode, Wolfgang Wrasidlo
  • Publication number: 20060110396
    Abstract: The present invention relates to the use of a ligand of CDw52 for the preparation of a medicament for the treatment of diseases that are related to CDw52 expressing degenerated macrophages. In particular, the present invention relates to the treatment of diseases such as MAS, LCH, HLH, and AML.
    Type: Application
    Filed: October 7, 2005
    Publication date: May 25, 2006
    Applicant: Charite-Universitaetsmedizin Berlin
    Inventors: Gerhard Gaedicke, Veit Krenn, Raphaela Guenther, Holger Lode